OxSonics

The core of OxSonics' offering is the SonoTran® platform, designed to overcome the challenge of poor drug penetration into solid tumors. The system works by co-administering proprietary, injectable 'SonoTran Particles' with an unmodified anti-cancer drug. These particles, which are optimized to pass into the tumor mass, carry stabilized gas bubbles. A dedicated, mobile ultrasound system is then used to target the tumor, causing the bubbles to undergo inertial cavitation (expansion and collapse). This creates a mechanical pumping effect that actively transports the co-administered drug deeper into and throughout the tumor tissue, enhancing its concentration and distribution. A key feature is the "see-as-you-treat" technology, which provides clinicians with real-time on-screen visualization and monitoring of the treatment area.

OxSonics is a privately held company backed by venture capital and angel investors. It has raised capital through multiple funding rounds, including a Series A in 2014 and a Series B in 2017, with investors like Longwall Venture Partners and Oxford University Innovation. The company's business model involves both in-house pipeline development and strategic partnerships with pharmaceutical and biotech companies. This collaborative approach allows OxSonics to combine its drug-agnostic platform with new or existing oncology drugs without requiring costly drug reformulation, aiming to improve efficacy, reduce toxicity, and potentially salvage failed therapeutic agents. The company began its first-in-human clinical trials in January 2022, evaluating the platform in patients with metastatic colorectal cancer.